The biochip market size is calculated at USD 14.37 billion in 2025 and is expected to reach around USD 42.15 billion by 2034, ...

About Vaxxas Vaxxas is a biotechnology company pioneering a needle-free vaccination technology designed to enhance immune response, reduce costs, and improve accessibility. The company recently ...

ObvioHealth, a global leader in digital clinical trial solutions, announced that it has signed a three-year agreement with Vaxxas, a clinical-stage biotechnology company pioneering a needle-free ...

Scientists at the Leibniz Institute of Photonic Technology (Leibniz IPHT) have developed a new microarray-based diagnostic ...

Key Highlights from ASHG 2025: A total of nine studies, presented as either oral sessions or posters, demonstrated the effectiveness of OGM in detecting novel SVs that can be missed by traditional ...

Objective: Translation of fertility risks through whole-exome sequencing of family lines to identify variants that explain patient’s clinical phenotypes. Methods: 1. Using techniques such as amniotic ...

The MarketWatch News Department was not involved in the creation of this content. -- Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via "patch" technology and utilizes ...

Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technology Research builds on Emory’s ...

Heidelberg, 10 th of June 2025 – PEPperPRINT, a global leader in peptide microarray technology, celebrates its 15 th anniversary with the launch of its next-generation peptide microarray platform: ...

Reported Data Supports the Potential Extension of HD-MAP Vaccine Delivery to Oncology Indications Recently published data generated by researchers at The University of Queensland and Vaxxas shows ...